



# High Oral Carriage of Non-*albicans* *Candida* spp. among HIV-infected individuals



Martha F. Mushi<sup>a</sup>, Conjester I. Mtemisika<sup>a</sup>, Oliver Bader<sup>b</sup>, Christine Bii<sup>c</sup>,  
Mariam M. Mirambo<sup>a</sup>, Uwe Groß<sup>b</sup>, Stephen E. Mshana<sup>a,\*</sup>

<sup>a</sup> Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences P.O. Box 1464 Mwanza, Tanzania

<sup>b</sup> Institute of Medical Microbiology, University Medical Center Kreuzberggring 57, 37075 Göttingen Germany

<sup>c</sup> Kenya Medical Research Institute, Center for Microbiology Research P.O. Box 54840 00200, Nairobi, Kenya

## ARTICLE INFO

### Article history:

Received 29 April 2016

Accepted 3 July 2016

**Corresponding Editor:** Eskild Petersen, Aarhus, Denmark

### Keywords:

Oral health

non-*Candida albicans* *Candida* spp.

HIV

## ABSTRACT

**Background:** Non-*albicans* *Candida* (NAC) spp. in immunocompromised patients are linked to invasive infections with narrow treatment choice. This study aimed at comparing the oral colonization of NAC spp. between HIV and non-HIV infected individuals in Mwanza, Tanzania.

**Method:** Oral rinse of 351 HIV-infected and 639 non-HIV infected individuals were collected between March and July 2015. Phenotypic identifications of *Candida* spp. was done using *Candida* Chromogenic agar and confirmed by MALDI-TOF MS.

**Results:** NAC spp. were detected in 36/351 (10.3%) HIV-infected individuals compared to 28/639 (4.4%) of non-HIV infected individuals;  $P=0.0003$ . In HIV infected individuals, commonly isolated NAC spp. were *Candida tropicalis*, 10(2.8%), *C. krusei* (*Issatschenki orientalis*) 9(2.6%) and *C. glabrata* 8(2.3%). While for non-HIV infected individuals *C. dubliniensis* 8(1.3%) and *C. tropicalis* 5(0.9%) were commonly detected. As CD4 count/ $\mu\text{l}$  decreases by one unit the risk of being colonized by NAC spp. among HIV infected individuals increases by 1% (OR 1.01, 95% CI: 1.001–1.004,  $P=0.001$ ).

**Conclusion:** The prevalence of NAC spp. is high among HIV-infected individuals with low CD4 count placing them at higher risk of invasive infections. Further studies to investigate the role of NAC spp. in causing invasive infections among immunocompromised patients are recommended.

© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Background

Oral candidiasis (OC) is one of the major opportunistic fungal infections that occur in over 90% of the HIV-infected individuals during the course of their illness.<sup>1</sup> It is one of the Acquired Immune Deficiency Syndromes (AIDS) prognostic indicators and a major predisposing factor to invasive fungal diseases like blood-stream *Candida* infections.<sup>2,3</sup> Oral cavity colonization by *Candida* spp. in the healthy population ranges from 17%–75% worldwide.<sup>4</sup> For decades, *Candida albicans* has been the major *Candida* spp. isolated

from oral cavity of both immunocompromised and immunocompetent individuals, accounting for 60%–80% of cases.<sup>5,6</sup> The emergence of non-*albicans* *Candida* (NAC) spp. which are more resistant to azoles causing oral candidiasis is of public health concern especially in resource constrained settings.<sup>2,3</sup> The common NAC spp. associated with oral candidiasis includes *C. glabrata*, *C. tropicalis*, *C. parapsilosis* and *C. krusei* (*Issatschenkia orientalis*).<sup>7–9</sup>

Oral candidiasis is among the indirect indicators for cell-mediated immunodeficiency and estimated to have >90% positive predictive value for invasive (e.g. blood stream) candidiasis.<sup>4,10,11</sup> Blood-stream *Candida* infections are the fourth-ranking hospital-related infection with mortality rates higher than bacterial blood-stream infections in USA.<sup>5,12,13</sup> With increased prevalence of immunocompromised patients in sub-Saharan Africa, there is widespread use of antifungal agents both for prophylaxis and treatment purposes.<sup>9</sup> This increased use has been associated with

\* Corresponding author. Department of Microbiology and Immunology, Catholic University of Health and Allied Sciences (CUHAS) P.O. BOX 1464 Mwanza, Tanzania.

E-mail addresses: [marthamushi@yahoo.com](mailto:marthamushi@yahoo.com) (M.F. Mushi), [conjestermtemisika@yahoo.com](mailto:conjestermtemisika@yahoo.com) (C.I. Mtemisika), [obader@med.uni-goettingen.de](mailto:obader@med.uni-goettingen.de) (O. Bader), [biichristine@gmail.com](mailto:biichristine@gmail.com) (C. Bii), [mmmirambo@gmail.com](mailto:mmmirambo@gmail.com) (M.M. Mirambo), [ugross@gwdg.de](mailto:ugross@gwdg.de) (U. Groß), [mshana72@yahoo.com](mailto:mshana72@yahoo.com) (S.E. Mshana).

augmented reports of antifungal resistance.<sup>14</sup> There is increase of some yeast species like *I. orientalis*, *C. inconspicua* and *C. norvegensis* which are intrinsically resistant to fluconazole being isolated from clinical specimens.<sup>15</sup> In addition, the increased use of antifungals especially azoles has resulted in multiple reports of fluconazole-resistant *C. glabrata*.<sup>14,15</sup>

In Tanzania, there are limited fungal diagnosis services available and data on *Candida* spp. colonization and subsequently causing infections in healthy individuals and immunocompromised patients are still scarce. This comparative study was designed to establish the prevalence and distributions of NAC spp. colonizing HIV-infected and non-HIV infected individuals.

## 2. Materials and Methods

### 2.1. Study design and cohort

This comparative cross-sectional study was conducted in Mwanza City, Tanzania between March and July 2015. Individuals aged 1–90 years without clinical signs of oral candidiasis were recruited. Sample size was obtained using Kish Lisle formula basing on the 30% prevalence of NAC spp. obtained from a study in Nigeria among HIV-infected individuals.<sup>16</sup> The minimum sample size obtained was 323 HIV-infected individuals. In order to compare the prevalence we also enrolled nearly double as many non-HIV infected individuals as in the control group. HIV-infected patients (n=351) were recruited from Care and Treatment Centre (CTC) at Bugando Medical Centre (BMC). Non-HIV infected individuals (n = 639) were recruited from primary school, secondary schools, university and patients relatives visiting BMC. HIV status was confirmed using the Tanzania National Rapid test algorithms protocol.<sup>17</sup>

### 2.2. Data collection and processing

Social demographic data of the study participants were collected using standardized data collection tool. For HIV-infected patients, the most recent CD4+ count was obtained from files. Oral rinse specimens were collected by having each participant hold 10 ml sterile normal saline in the mouth for 60 seconds, then spit in the sterile container as previously described.<sup>18</sup> Samples were inoculated on Sabouraud's Dextrose Agar supplemented with 50 mg/ml gentamicin and 50 mg/ml chloramphenicol (SDA) (Oxoid, Basingstoke RG24 8PW, UK). Plates were aerobically incubated at 35 °C for 24–48 h. Preliminary spp. identification was done on CHROMagar (OXOID, Hampshire, England) as previously described.<sup>19</sup> The confirmation was done using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MALDI Biotyper, Bruker Daltonics, Bremen, Germany) on extracted cells harvested from SDA.<sup>20,21</sup>

## 3. Data analysis

Data analysis was done using STATA version 11. Categorical variables (sex, antibiotic use, use of HAART and trimethoprim/sulphamethaxazole (SXT) prophylaxes use) were summarized in the form of proportions and frequency tables, whereas median (interquartile range) was used to summarize continuous variables (age and CD4 count). Univariate and multivariate logistic regression analysis was done to determine factors associated with non-albicans *Candida* colonization. Factors with 95% confidence interval (CI) and p-value of less than 0.05 were considered statistically significant. The medians CD4 count among HIV infected individuals colonized and non-colonized with NAC spp. were compared using Wilcoxon rank-sum (Mann-Whitney) test.

### 3.1. Ethical consideration

Ethical clearance for conducting this study was granted by joint CUHAS/BMC research ethics and review committee with certificate number CREC/048/2014. All participants above 18 years of age were requested to sign the written informed consent form and for participants below 18 years their parents/guardians were requested to assents for them before recruitment. All patient-related information was stored in a pseudonymized form.

## 4. Results

The median age of HIV-infected patients was 38 (IQR 31–46) years while that of non-HIV infected individuals was 30 (IQR 26–36) years. The majority of HIV-infected patients (160/351, 45.6%) had a history of antibiotics use two weeks prior enrolment. The median CD4 count of the HIV-infected patients was 372.5 (IQR 195.5–559.5) cells/ $\mu$ l (Table 1).

*Candida albicans* was the commonest spp. detected in both groups 119 (n = 351, 33.90%) of HIV-infected and 146 (n = 639, 22.9%) of non-HIV infected population (p = 0.023). NAC spp. carriage was detected in 64 (n = 990, 6.46%) of the study participants. Of HIV-infected patients, 36/351 (10.3%) carried NAC spp., as compared to only 28/639 (4.4%) among non-HIV infected (P = 0.0003). Only one HIV infected participant was colonized by two NAC spp.

Of 351 HIV infected individuals; 10(2.8%), 9(2.6%) and 8(2.3%) had *Candida tropicalis*, *C. krusei* (*Issatschenki orientalis*) and *C. glabrata* respectively, while of 639 non-HIV infected individuals, 8(1.3%) and 5(0.9%) were colonized with *C. dubliniensis* and *C. tropicalis* respectively (Table 2). Non-albicans *Candida* spp. detected from HIV infected individuals were *C. tropicalis* 10(27.8%), *I. orientalis* 9(25%), *C. glabrata* 8(22.2%) and others 9(25%) (Table 2). Out of 15 *C. tropicalis*, 12 *I. orientalis* and 12 *C. glabrata* detected 10, 9 and 8 respectively, were from HIV infected

**Table 1**  
Social demographic data of the study population

Variable	HIV positive (n = 351)	Control (n = 639)	P-value
<b>Age (years)</b>			
Median (IQR)	38(31–46)	30(26–36)	<0.001
<b>Sex</b>			
Female	262	462	
Male	89	177	0.426
<b>Antibiotic use</b>			
Yes	160(45.6%)	33(5.2%)	
No	191(54.4%)	606(94.8%)	<0.001
<b>CD4</b>			
Median(IQR)	372.5(195.5–559.5)	NA	NA
<b>HAART</b>			
Yes	343(97.2%)	NA	NA
<b>SXT prophylaxis</b>			
Yes	321(91.5%)	NA	NA

\*SXT: trimethoprim/sulphamethaxazole

**Table 2**  
Distributions of *Candida* spp. among HIV and non HIV infected populations

<i>Candida</i> spp.	HIV positive N = 351, (n/N)%	Health control N = 639, (n/N)%	P value
<b>C. albicans (265)</b>	119(33.9)	146(22.9)	0.023
<b>C. tropicalis (15)</b>	10(2.8)	5 (0.9)	0.006
<b>I. orientalis (12)</b>	9 (2.6)	3 (0.5)	0.002
<b>C. glabrata (12)</b>	8 (2.3)	4 (0.6)	0.012
<b>C. parapsilosis (11)</b>	7 (1)	4 (0.6)	0.242
<b>C. dubliniensis (11)</b>	3 (0.8)	8 (1.3)	0.763
<b>C. norvegensis (2)</b>	0	2 (0.3)	NA
<b>C. lusitaniae (2)</b>	0	2 (0.3)	NA

**Table 3**  
Factors associated with non-albicans *Candida* colonization

Predictor	NCA positivity	OR(95%CI)	P value	Adjusted OR(95%CI)	Adjusted P value
<b>Sub analysis of HIV infected patients</b>					
<b>Median Age*</b>	36(27-43)	0.99(0.96-1.01)	0.352	0.992(0.97-1.02)	0.567
<b>Sex</b>					
Male (89)	10(11.2%)	1			
Female (262)	26(9.92%)	0.87(0.4-1.9)	0.725	1.001(0.43-2.8)	0.996
<b>Median CD4*</b>	251(120-380)	0.99(0.995-0.999)	0.007**	0.99(0.996-0.999)	0.01**
<b>Antibiotic use</b>					
No (191)	15(7.85)	1			
Yes (160)	21(13.13)	1.78(0.88-3.56)	0.108	2.2(1.03-4.74)	0.042**
<b>SXT</b>					
No (30)	3(10.00)	1			
Yes (321)	33(10.28)	1.03(0.29-3.58)	0.961	1.6(0.26-9.62)	0.62
<b>HAART</b>					
No (8)	1(12.5)	1			
Yes (343)	35(10.2)	0.79(0.95-6.65)	0.833	0.82(0.1-11.4)	0.88
<b>Sub analysis of health control</b>					
<b>Median Age*</b>		1.02(0.99-10.3)	0.073	1.02(0.99-1.04)	0.07
<b>Sex</b>					
Male (177)	7(3.95%)	1			
Women (462)	21(4.55%)	1.16(0.48-2.77)	0.744	1.2(0.52-3.03)	0.621
<b>Antibiotic use</b>					
No (606)	26(4.29%)	1			
Yes (33)	2(6.06%)	1.44(0.33-6.34)	0.63	1.3(0.29-5.84)	0.72

**Note:** \*median (Inter quartile range), \*\* statistically significant variables and NCA positivity is Non albicans *Candida* positivity.

individuals while *C. dubliniensis* were predominantly detected from HIV uninfected individuals 8/11 Table 2.

The median CD4 cell count among HIV-infected patients colonized by non-*albicans Candida* spp. was 251 (IQR 170-380) cells/ $\mu$ l, while for those not colonized by NAC spp. was 473 (IQR 304-673.5) cells/ $\mu$ l,  $P < 0.001$ .

On multivariate logistic regression analysis, among HIV-infected individuals, as CD4 decreases by one unit the risk of being colonized by NAC spp. increases by 1% (OR 1.01, 95% CI; 1.001-1.004,  $P = 0.001$ ). Among HIV-infected individuals, those with history of antibiotic use two weeks prior recruitment to the study were more (OR = 2.2,  $p = 0.042$ ) colonized by NAC spp. than those with no history of antibiotic use (Table 3).

#### Non-*albicans Candida* colonization among HIV-infected individuals without antibiotic use

Of 191 HIV-infected individuals without history of antibiotic use, 15 (7.85%) were colonized by NAC spp., as compared to 26 (4.3%) of 606 HIV-uninfected individuals without history of antibiotic use  $p = 0.026$ .

#### 5. Discussion

Oral yeast (mainly *Candida* spp.) colonization remains one of the major initial processes that can progress to infections if the innate and adaptive immune system is disrupted.<sup>22</sup> The increased isolation of NAC spp. colonizing oral cavity is of public health concern because of the possibility of *Candida* infections caused by azole-resistant NAC spp., which are difficult to treat.<sup>3,23</sup> As it was previously reported,<sup>2,3,22</sup> HIV-infected individuals in the current study had significantly higher rates of colonization by NAC spp. than non-HIV infected individuals, which can be explained by their compromised immune status. The prevalence obtained in this study is similar to that reported by Cartledge *et al* among HIV-infected individuals.<sup>23</sup>

Multiple therapies and here mainly antibiotic treatment among HIV-infected individuals is one of the factors that can influence oral *Candida* colonization. In the current study, among HIV-infected individuals history of antibiotic use was found to be a significant factor that can lead to oral colonization by NAC spp. This

phenomenon has also been reported previously by Canon *et al*,<sup>24</sup> whereby most of the participants with history of antibiotic use were found to be colonized by NAC spp. The ability of the broad-spectrum antibiotics to alter the normal microbial flora by killing the bacteria and allowing the proliferation of *Candida* is thought to explain the observed fact.<sup>15,25</sup> However, HIV infection alone without antibiotic use might also have influence on colonization by NAC spp. as evidenced in this study. HIV-infected individuals without history of antibiotic use had significantly higher colonization rates by NAC spp. than HIV-uninfected individual without history of antibiotic use.

*Candida tropicalis*, *I. orientalis*, *C. glabrata* and *C. parapsilosis* were the most frequent NAC spp. isolated from HIV-infected individual in the current study. This is of public health concern because some of these *Candida* spp. are intrinsic resistant to fluconazole which is the commonly used azole in developing countries.<sup>26-29</sup> *I. orientalis* is known to be natural resistant to fluconazole while *C. glabrata* is highly variable with an elevated ability to develop resistance.<sup>30</sup>

With an un-established fungal diagnosis to species level in resource-constrained settings like Tanzania, the overuse of fluconazole in HIV and non HIV patients for prophylaxis and empirical treatment might increase the problem of treatment failure for NAC infections. This signifies the importance of improving fungal diagnostics especially in sub-Saharan Africa.

Findings of this study suggest that decrease of CD4 count as the marker for immune status has influence on *Candida* carriage. This was further confirmed by the fact that the use of highly active antiretroviral therapy (HAART) among HIV-infected individuals was found to reduce the risk of oral NAC spp. colonization in the current study. This same finding has also previously been reported elsewhere.<sup>2,31</sup>

#### 6. Conclusion

The prevalence of NAC spp. is high among HIV-infected individuals with low CD4 count, placing them at higher risk of invasive infections caused by these pathogens. Further studies should be done to investigate the role of non-*albicans Candida* spp. in causing invasive fungi infections among immunocompromised patients.

## Acknowledgement

This work was supported by Microbiology Immunology department CUHAS and Institute of Medical Microbiology, University Medical Center Goettingen, Germany. The authors would like to thank Agnieszka Goretzki, Vitus Silago and Emilia Gómez for expert technical assistance.

**Conflict of interest:** Authors declare no conflict of interest in publishing this manuscript.

**Ethical consideration:** Ethical clearance for conducting this study was granted by joint CUHAS/BMC research ethics and review committee with certificate number CREC/048/2014. All participants above 18 years of age were requested to sign the written informed consent form and for participants below 18 years their parents/guardians were requested to assent for them before recruitment. All patient-related information was stored in a pseudonymized form.

## References

- Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein Jr W, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. *Aids* 1991;**5**(5):519–26.
- Thanyasrisung P, Kesakomol P, Pipattanagovit P, Youngnak-Piboonratanakit P, Pitiphat W, Matangkasombut O. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. *Journal of medical microbiology* 2014;**63**(5):753–9.
- Meurman J, Siikala E, Richardson M, Rautemaa R. Non-Candida albicans Candida yeasts of the oral cavity. In: Communicating current research and educational topics and trends in applied microbiology Microbiology book series Badajoz. Formatex; 2007: 719–31.
- Nittayananta W, Jealae S, Winn T. Oral Candida in HIV infected heterosexuals and intravenous drug users in Thailand. *Journal of oral pathology & medicine* 2001;**30**(6):347–54.
- Kuhn DM, Mukherjee PK, Clark TA, Pujol C, Chandra J, Hajjeh RA, et al. Candida parapsilosis characterization in an outbreak setting. *Emerg Infect Dis* 2004;**10**(6): 1074–81.
- Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata, an emerging oral opportunistic pathogen. *Journal of dental research* 2007;**86**(3):204–15.
- Dronda F, Alonso-Sanz M, Laguna F, Chaves F, Martinez-Suarez J, Rodriguez-Tudela J, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. *European Journal of Clinical Microbiology and Infectious Diseases* 1996;**15**(6):446–52.
- Cannon R, Chaffin W. Oral colonization by Candida albicans. *Critical Reviews in Oral Biology & Medicine* 1999;**10**(3):359–83.
- Belazi M, Velegraki A, Koussidou Eremondi T, Andreadis D, Hini S, Arsenis G, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. *Oral microbiology and immunology* 2004;**19**(6):347–51.
- Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. *The American journal of gastroenterology* 1995;**90**(11):1938–41.
- Tumbarello M, Calderola G, Tacconelli E, Morace G, Posteraro B, Cauda R, et al. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. *Journal of Antimicrobial Chemotherapy* 1996;**38**(4):691–9.
- Safdar A, Chaturvedi V, Cross EW, Park S, Bernard EM, Armstrong D, et al. Prospective study of Candida species in patients at a comprehensive cancer center. *Antimicrobial agents and chemotherapy* 2001;**45**(7):2129–33.
- Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. *Clinical infectious diseases* 1999;**29**(5): 1164–70.
- White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. *Clinical microbiology reviews* 1998;**11**(2):382–402.
- Moran GP, Sullivan DJ, Coleman DC. Emergence of non-Candida albicans Candida species as pathogens. Washington, DC: Candida and candidiasis ASM Press; 2002 37–53.
- Nweze EI, Ogbonnaya UL. Oral Candida isolates among HIV-infected subjects in Nigeria. *Journal of Microbiology Immunology and Infection* 2011;**44**(3):172–7.
- NACP: **National guidelines for management of HIV/AIDS. Tanzania 2012, 4th edition**
- Fisher B, Lamey PJ, Samaranyake L, MacFarlane T, Frier B. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. *Journal of Oral Pathology & Medicine* 1987;**16**(5):282–4.
- Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. *Journal of clinical microbiology* 1996;**34**(1):58–61.
- Wieser A, Schneider L, Jung J, Schubert S. MALDI-TOF MS in microbiological diagnostics—identification of microorganisms and beyond (mini review). *Applied microbiology and biotechnology* 2012;**93**(3):965–74.
- Bader O, Weig M, Taverne Ghadwal L, Lugert R, Gross U, Kuhns M. Improved clinical laboratory identification of human pathogenic yeasts by matrix assisted laser desorption ionization time of flight mass spectrometry. *Clinical Microbiology and Infection* 2011;**17**(9):1359–65.
- Fong IW, Manuel L, Burford-Mason A. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. *Clinical and investigative medicine* 1997;**20**(2):85.
- Cartledge J, Midgley J, Gazzard B. Non-albicansoralcandidosis in HIV-positive patients. *Journal of Antimicrobial Chemotherapy* 1999;**43**(3):419–22.
- Cannon R, Holmes A, Mason A, Monk B. Oral Candida: clearance, colonization, or candidiasis? *Journal of Dental Research* 1995;**74**(5):1152–61.
- Meurman J, Pajukoski H, Snellman S, Zeiler S, Sulkava R. Oral infections in home-living elderly patients admitted to an acute geriatric ward. *Journal of dental research* 1997;**76**(6):1271–6.
- Rex JH, Rinaldi M, Pfaller M. Resistance of Candida species to fluconazole. *Antimicrobial agents and chemotherapy* 1995;**39**(1):1.
- Brammer K, Farrow P, Faulkner J. Pharmacokinetics and tissue penetration of fluconazole in humans. *Review of Infectious Diseases* 1990;**12**(Supplement 3): S318–26.
- Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. *Antimicrobial agents and chemotherapy* 1988;**32**(1):1–8.
- Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. *AIDS research and human retroviruses* 1999;**15**(16):1405–12.
- Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases* 2015; civ933.
- Gupta E, Vajpayee M, Xess I, Seth P. Oral candidiasis in HIV-infected patients and its relation to CD4+ counts: an adjunct clinical marker of HIV disease progression. *Tropical doctor* 2006;**36**(2):127.